{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:38:32Z","timestamp":1773232712238,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jiph.2025.102987","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:53:41Z","timestamp":1759996421000},"page":"102987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study"],"prefix":"10.1016","volume":"18","author":[{"given":"Rui","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youhong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pulin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghe","family":"Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daxiong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jiph.2025.102987_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J Med Virol"},{"issue":"18","key":"10.1016\/j.jiph.2025.102987_bib2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jiph.2025.102987_bib3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"32","author":"Li","year":"2022","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.jiph.2025.102987_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41392-022-00997-x","article-title":"SARS-CoV-2 omicron variant: recent progress and future perspectives","volume":"7","author":"Fan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.jiph.2025.102987_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"10.1016\/j.jiph.2025.102987_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41422-022-00619-9","article-title":"Reduced interferon antagonism but similar drug sensitivity in omicron variant compared to delta variant of SARS-CoV-2 isolates","volume":"32","author":"Bojkova","year":"2022","journal-title":"Cell Res"},{"issue":"10","key":"10.1016\/j.jiph.2025.102987_bib7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2025.102987_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115503","article-title":"Bench-to-bedside: innovation of small molecule anti-SARS-CoV-2 drugs in China","volume":"257","author":"Yang","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.jiph.2025.102987_bib9","article-title":"The first Chinese oral anti-COVID-19 drug azvudine launched","volume":"3","author":"Yu","year":"2022","journal-title":"Innov (Camb)"},{"issue":"18","key":"10.1016\/j.jiph.2025.102987_bib10","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3390\/healthcare13182319","article-title":"Policy-Driven digital health interventions for health promotion and disease prevention: a systematic review of clinical and environmental outcomes","volume":"13","author":"Faizan","year":"2025","journal-title":"Healthcare"},{"issue":"19","key":"10.1016\/j.jiph.2025.102987_bib11","article-title":"A randomized, Open-Label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study","volume":"7","author":"Ren","year":"2020","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"10.1016\/j.jiph.2025.102987_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28947","article-title":"Oral azvudine for mild-to-moderate COVID-19 in high risk, nonhospitalized adults: results of a real-world study","volume":"95","author":"Yang","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.jiph.2025.102987_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101981","article-title":"Oral azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study","volume":"59","author":"Sun","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"10377","key":"10.1016\/j.jiph.2025.102987_bib14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(23)00129-0","article-title":"Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis","volume":"401","author":"Pan","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2025.102987_bib15","unstructured":"General Office of the National Health Commission. Diagnosis and treatment protocol for COVID-19 in China (trial version 10). 2023 [cited 2023]Available from: \u3008https:\/\/www.gov.cn\/zhengce\/zhengceku\/2023-01\/06\/content_5735343.htm\u3009."},{"issue":"1","key":"10.1016\/j.jiph.2025.102987_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","article-title":"Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19","volume":"181","author":"Gupta","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jiph.2025.102987_bib17","unstructured":"Organization WH. COVID-19 Therapeutic Trial Synopsis. 2020 2020.2.18 [cited 2022 2022.02.18]Available from: \u3008https:\/\/www.who.int\/publications\/i\/item\/covid-19-therapeutic-trial-synopsis\u3009."},{"key":"10.1016\/j.jiph.2025.102987_bib18","unstructured":"Propensity score matching in SPSS. 2012 [cited 2012]. Available from: \u3008https:\/\/arxiv.org\/abs\/1201.6385\u3009."},{"issue":"7172","key":"10.1016\/j.jiph.2025.102987_bib19","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","article-title":"Survival probabilities (the Kaplan-Meier method)","volume":"317","author":"Bland","year":"1998","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.jiph.2025.102987_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28756","article-title":"Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a retrospective cohort study","volume":"95","author":"Deng","year":"2023","journal-title":"J Med Virol"},{"issue":"15","key":"10.1016\/j.jiph.2025.102987_bib21","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1021\/acs.jmedchem.0c00940","article-title":"Mechanistic insight into antiretroviral potency of 2\u2032-Deoxy-2\u2032-\u03b2-fluoro-4\u2032-azidocytidine (FNC) with a Long-Lasting effect on HIV-1 prevention","volume":"63","author":"Sun","year":"2020","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.jiph.2025.102987_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41392-021-00835-6","article-title":"Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.jiph.2025.102987_bib23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1021\/acs.accounts.1c00697","article-title":"4'-Modified nucleosides for antiviral drug discovery: achievements and perspectives","volume":"55","author":"Chang","year":"2022","journal-title":"Acc Chem Res"},{"issue":"2","key":"10.1016\/j.jiph.2025.102987_bib24","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/j.jinf.2023.05.012","article-title":"Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities","volume":"87","author":"Dian","year":"2023","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.jiph.2025.102987_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/a-1300-2550","article-title":"The role of glucocorticoids in the management of COVID-19","volume":"53","author":"Alexaki","year":"2021","journal-title":"Horm Metab Res"},{"issue":"5","key":"10.1016\/j.jiph.2025.102987_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252057","article-title":"Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia","volume":"16","author":"Pinz\u00f3n","year":"2021","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jiph.2025.102987_bib27","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciaa829","article-title":"High-dose but not Low-dose corticosteroids potentially delay viral shedding of patients with COVID-19","volume":"72","author":"Li","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2025.102987_bib28","article-title":"Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients","volume":"10","author":"de Souza","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"10.1016\/j.jiph.2025.102987_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20153","article-title":"Efficacy and safety of azvudine in patients with COVID-19: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jiph.2025.102987_bib30","article-title":"Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jiph.2025.102987_bib31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41392-022-01249-8","article-title":"Small molecules in the treatment of COVID-19","volume":"7","author":"Lei","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.jiph.2025.102987_bib32","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1473-3099(22)00119-0","article-title":"Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach","volume":"22","author":"Dal-R\u00e9","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jiph.2025.102987_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37979-0","article-title":"Using real-world evidence data and digital monitoring to analyze the hepatotoxic profiles of biologics across more than two million patients","volume":"13","author":"Banerjee","year":"2023","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.jiph.2025.102987_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28926","article-title":"Evaluate clinical effectiveness of azvudine with data rather than speculation","volume":"95","author":"Li","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.jiph.2025.102987_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1053814","article-title":"How to use COVID-19 antiviral drugs in patients with chronic kidney disease","volume":"14","author":"Kale","year":"2023","journal-title":"Front Pharm"},{"issue":"2","key":"10.1016\/j.jiph.2025.102987_bib36","first-page":"103","article-title":"All-cause mortality in moderate and severe COVID-19 patients with myocardial injury receiving versus not receiving azvudine: a propensity score-matched analysis","volume":"8","author":"Chen","year":"2023","journal-title":"Cardiol"},{"issue":"8","key":"10.1016\/j.jiph.2025.102987_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29007","article-title":"Azvudine therapy of common COVID-19 in hemodialysis patients","volume":"95","author":"Shang","year":"2023","journal-title":"J Med Virol"},{"issue":"15","key":"10.1016\/j.jiph.2025.102987_bib38","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"issue":"10287","key":"10.1016\/j.jiph.2025.102987_bib39","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet (Lond Engl)"},{"issue":"4","key":"10.1016\/j.jiph.2025.102987_bib40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1473-3099(22)00732-0","article-title":"Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study","volume":"23","author":"Tsang","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2025.102987_bib41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejps.2017.05.009","article-title":"Intestinal absorption mechanisms of 2\u2032-deoxy-2\u2032-\u03b2-fluoro-4\u2032-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein","volume":"105","author":"Liu","year":"2017","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"10.1016\/j.jiph.2025.102987_bib42","first-page":"503","article-title":"Effects of the antiretroviral drug 2\u2032-deoxy-2\u2032-\u03b2-fluoro-4\u2032-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions","volume":"73","author":"Liu","year":"2018","journal-title":"Pharmazie"},{"issue":"3","key":"10.1016\/j.jiph.2025.102987_bib43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/08989621.2023.2269083","article-title":"Spin in randomized controlled trials of pharmacology in COVID-19: a systematic review","volume":"32","author":"Oh","year":"2025","journal-title":"Acc Res"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125003363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125003363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:08:00Z","timestamp":1773158880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034125003363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1876034125003363"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102987","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"102987"}}